|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
van Meerbeeck JP, Fennell DA and De
Ruysscher DK: Small-cell lung cancer. Lancet. 378:1741–1755. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu W, Ha M and Yin N: Combination of
platelet count and lymphocyte to monocyte ratio is a prognostic
factor in patients undergoing surgery for non-small cell lung
cancer. Oncotarget. 8:73198–73207. 2017.PubMed/NCBI
|
|
5
|
Jones JI and Clemmons DR: Insulin-like
growth factors and their binding proteins: Biological actions.
Endocr Rev. 16:3–34. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Le Roith D: Seminars in medicine of the
Beth Israel deaconess medical center. Insulin-like growth factors.
N Engl J Med. 336:633–640. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
LeRoith D: Insulin-like growth factor
receptors and binding proteins. Baillieres Clin Endocrinol Metab.
10:49–73. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Clemmons DR: Insulin-like growth factor
binding proteins and their role in controlling IGF actions.
Cytokine Growth Factor Rev. 8:45–62. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hu Q, Zhou Y, Ying K and Ruan W: IGFBP, a
novel target of lung cancer? Clin Chim Acta. 466:172–177. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
He Y, Zhou Z, Hofstetter WL, Zhou Y, Hu W,
Guo C, Wang L, Guo W, Pataer A, Correa AM, et al: Aberrant
expression of proteins involved in signal transduction and DNA
repair pathways in lung cancer and their association with clinical
parameters. PLoS One. 7:e310872012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guo C, Lu H, Gao W, Wang L, Lu K, Wu S,
Pataer A, Huang M, El-Zein R, Lin T, et al: Insulin-like growth
factor binding protein-2 level is increased in blood of lung cancer
patients and associated with poor survival. PLoS One. 8:e749732013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee DY, Kim SJ and Lee YC: Serum
insulin-like growth factor (IGF)-I and IGF-binding proteins in lung
cancer patients. J Korean Med Sci. 14:401–404. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Z, Wang Z, Liang Z, Liu J, Shi W, Bai
P, Lin X, Magaye R and Zhao J: Expression and clinical significance
of IGF-1, IGFBP-3, and IGFBP-7 in serum and lung cancer tissues
from patients with non-small cell lung cancer. Onco Targets Ther.
6:1437–1444. 2013.PubMed/NCBI
|
|
14
|
Zhang Y, Ying X, Han S, Wang J, Zhou X,
Bai E, Zhang J and Zhu Q: Autoantibodies against insulin-like
growth factor-binding protein-2 as a serological biomarker in the
diagnosis of lung cancer. Int J Oncol. 42:93–100. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chang YS, Kong G, Sun S, Liu D, El-Naggar
AK, Khuri FR, Hong WK and Lee HY: Clinical significance of
insulin-like growth factor-binding protein-3 expression in stage I
non-small cell lung cancer. Clin Cancer Res. 8:3796–3802.
2002.PubMed/NCBI
|
|
16
|
Kubasiak JC, Seder CW, Pithadia R, Basu S,
Fhied C, Phillips WW, Daly S, Shersher DD, Yoder MA, Chmielewski G,
et al: Value of circulating insulin-like growth factor-associated
proteins for the detection of stage I non-small cell lung cancer. J
Thorac Cardiovasc Surg. 149:727–734.e1-3. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cao H, Wang G, Meng L, Shen H, Feng Z, Liu
Q and Du J: Association between circulating levels of IGF-1 and
IGFBP-3 and lung cancer risk: A meta-analysis. PLoS One.
7:e498842012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profling and interactive analyses. Nucleic Acids Res. 45((W1)):
W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Uhlén M, Fagerberg L, Hallström BM,
Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C,
Sjöstedt E, Asplund A, et al: Proteomics. Tissue-based map of the
human proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gyorffy B, Lánczky A and Szállási Z:
Implementing an online tool for genome-wide validation of
survival-associated biomarkers in ovariancancer using microarray
data from 1287 patients. Endocr Relat Cancer. 19:197–208. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Montojo J, Zuberi K, Rodriguez H, Bader GD
and Morris Q: GeneMANIA: Fast gene network construction and
function prediction for Cytoscape. F1000Res. 3:1532014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang da W, Sherman BT and Lempicki RA:
Bioinformatics enrichment tools: paths toward the comprehensive
functional analysis of large gene lists. Nucleic Acids Res.
37:1–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Baxter RC: IGF binding proteins in cancer:
Mechanistic and clinical insights. Nat Rev Cancer. 14:329–341.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ammoun S, Schmid MC, Zhou L, Ristic N,
Ercolano E, Hilton DA, Perks CM and Hanemann CO: Insulin-like
growth factor-binding protein-1 (IGFBP-1) regulates human
schwannoma proliferation, adhesion and survival. Oncogene.
31:1710–1722. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Figueroa JA, Sharma J, Jackson JG,
McDermott MJ, Hilsenbeck SG and Yee D: Recombinant insulin-like
growth factor binding protein-1 inhibits IGF-I, serum, and
estrogen-dependent growth of MCF-7 human breast cancer cells. J
Cell Physiol. 157:229–236. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yamada H, Iijima K, Tomita O, Taguchi T,
Miharu M, Kobayashi K, Okita H, Saito M, Shimizu T and Kiyokawa N:
Effects of insulin-like growth factor-1 on B-cell precursor acute
lymphoblastic leukemia. Int J Hematol. 97:73–82. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Leu JI, Crissey MA and Taub R: Massive
hepatic apoptosis associated with TGF-beta1 activation after Fas
ligand treatment of IGF binding protein-1-deficient mice. J Clin
Invest. 111:129–139. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sharma J, Gray KP, Evan C, Nakabayashi M,
Fichorova R, Rider J, Mucci L, Kantoff PW and Sweeney CJ: Elevated
insulin-like growth factor binding protein-1 (IGFBP-1) in men with
metastatic prostate cancer starting androgen deprivation therapy
(ADT) is associated with shorter time to castration resistance and
overall survival. Prostate. 74:225–234. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cao Y, Nimptsch K, Shui IM, Platz EA, Wu
K, Pollak MN, Kenfield SA, Stampfer MJ and Giovannucci EL:
Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer.
Int J Cancer. 136:2418–2426. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yao X, Sun S, Zhou X, Guo W and Zhang L:
IGF-binding protein 2 is a candidate target of therapeutic
potential in cancer. Tumour Biol. 37:1451–1459. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Maciejczyk A, Szelachowska J, Czapiga B,
Matkowski R, Hałoń A, Györffy B and Surowiak P: Elevated BUBR1
expression is associated with poor survival in early breast cancer
patients: 15-year follow-up analysis. J Histochem Cytochem.
61:330–339. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Reeve JG, Morgan J, Schwander J and
Bleehen NM: Role for membrane and secreted insulin-like growth
factor-binding protein-2 in the regulation of insulin-like growth
factor action in lung tumors. Cancer Res. 53:4680–4685.
1993.PubMed/NCBI
|
|
35
|
Yazawa T, Sato H, Shimoyamada H, Okudela
K, Woo T, Tajiri M, Ogura T, Ogawa N, Suzuki T, Mitsui H, et al:
Neuroendocrine cancer-specific up-regulating mechanism of
insulin-like growth factor binding protein-2 in small cell lung
cancer. Am J Pathol. 175:976–987. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fürstenberger G and Senn HJ: Insulin-like
growth factors and cancer. Lancet Oncol. 3:298–302. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee HY, Chun KH, Liu B, Wiehle SA,
Cristiano RJ, Hong WK, Cohen P and Kurie JM: Insulin-like growth
factor binding protein-3 inhibits the growth of non-small cell lung
cancer. Cancer Res. 62:3530–3537. 2002.PubMed/NCBI
|
|
38
|
Alami N, Page V, Yu Q, Jerome L, Paterson
J, Shiry L and Leyland-Jones B: Recombinant human insulin-like
growth factor-binding protein 3 inhibits tumor growth and targets
the Akt pathway in lung and colon cancer models. Growth Horm IGF
Res. 18:487–496. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hochscheid R, Jaques G and Wegmann B:
Transfection of human insulin-like growth factor-binding protein 3
gene inhibits cell growth and tumorigenicity: A cell culture model
for lung cancer. J Endocrinol. 166:553–563. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kim JH, Choi DS, Lee OH, Oh SH, Lippman SM
and Lee HY: Antiangiogenic antitumor activities of IGFBP-3 are
mediated by IGF-independent suppression of Erk1/2 activation and
Egr-1-mediated transcriptional events. Blood. 118:2622–2631. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang HH, Wang YC, Wu DW, Hung CS, Chen CY
and Lee H: Targeting insulin-like growth factor-binding protein-3
by microRNA-125b promotes tumor invasion and poor outcomes in
non-small-cell lung cancer. Tumour Biol.
39:10104283176943162017.PubMed/NCBI
|
|
42
|
Han JY, Choi BG, Choi JY, Lee SY and Ju
SY: The prognostic significance of pretreatment plasma levels of
insulin-like growth factor (IGF)-1, IGF-2, and IGF binding
protein-3 in patients with advanced non-small cell lung cancer.
Lung Cancer. 54:227–234. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Walker G, MacLeod K, Williams AR, Cameron
DA, Smyth JF and Langdon SP: Insulin-like growth factor binding
proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine
responsiveness in patients with ovarian cancer. Clin Cancer Res.
13:1438–1444. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Butt AJ, Dickson KA, McDougall F and
Baxter RC: Insulin-like growth factor-binding protein-5 inhibits
the growth of human breast cancer cells in vitro and in vivo. J
Biol Chem. 278:29676–29685. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tanno B, Cesi V, Vitali R, Sesti F,
Giuffrida ML, Mancini C, Calabretta B and Raschellà G: Silencing of
endogenous IGFBP-5 by micro RNA interference affects proliferation,
apoptosis and differentiation of neuroblastoma cells. Cell Death
Differ. 12:213–223. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Johnson SK and Haun RS: Insulin-like
growth factor binding protein-5 influences pancreatic cancer cell
growth. World J Gastroenterol. 15:3355–3366. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yao R, Wang Y, Lubet RA and You M:
Differentially expressed genes associated with mouse lung tumor
progression. Oncogene. 21:5814–5821. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sueoka N, Lee HY, Wiehle S, Cristiano RJ,
Fang B, Ji L, Roth JA, Hong WK, Cohen P and Kurie JM: Insulin-like
growth factor binding protein-6 activates programmed cell death in
non-small cell lung cancer cells. Oncogene. 19:4432–4436. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Koyama N, Zhang J, Huqun, Miyazawa H,
Tanaka T, Su X and Hagiwara K: Identification of IGFBP-6 as an
effector of the tumor suppressor activity of SEMA3B. Oncogene.
27:6581–6589. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kannan K, Amariglio N, Rechavi G,
Jakob-Hirsch J, Kela I, Kaminski N, Getz G, Domany E and Givol D:
DNA microarrays identification of primary and secondary target
genes regulated by p53. Oncogene. 20:2225–2234. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Bartram I, Erben U, Ortiz-Tanchez J,
Blunert K, Schlee C, Neumann M, Heesch S and Baldus CD: Inhibition
of IGF1-R overcomes IGFBP7-induced chemotherapy resistance in
T-ALL. BMC Cancer. 15:6632015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Gutschner T, Hämmerle M, Pazaitis N, Bley
N, Fiskin E, Uckelmann H, Heim A, Groβ M, Hofmann N, Geffers R, et
al: Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1)
is an important protumorigenic factor in hepatocellular carcinoma.
Hepatology. 59:1900–1911. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kawasaki T, Nosho K, Ohnishi M, Suemoto Y,
Kirkner GJ, Fuchs CS and Ogino S: IGFBP3 promoter methylation in
colorectal cancer: Relationship with microsatellite instability,
CpG island methylator phenotype, and p53. Neoplasia. 9:1091–1098.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Bialous SA and Sarna L: Lung cancer and
tobacco: What is new? Nurs Clin North Am. 52:53–63. 2017.
View Article : Google Scholar : PubMed/NCBI
|
